Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; magnesium stearate; ethylcellulose; polyethylene glycol monomethyl ether; purified talc; maize starch; propylene glycol - ethambutol gh is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol gh should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised..

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: purified talc; magnesium stearate; hypromellose; titanium dioxide; colloidal anhydrous silica; propylene glycol; ethylcellulose; polyethylene glycol monomethyl ether; maize starch; povidone - ethambutol gh is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid plus rifampicin; or ? ethambutol plus isoniazid plus streptomycin,then continuing with a two drug regimen such as,? ethambutol plus isoniazid; or ? ethambutol plus rifampicin.,in patients who have received previous antituberculosis therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment cases ethambutol gh should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilised.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hcl is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ethambutol hcl plus isoniazidethambutol hcl plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hcl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with e

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - ethambutol hydrochloride - film-coated tablet - 100 milligram(s) - other drugs for treatment of tuberculosis; ethambutol

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - ethambutol hydrochloride - film-coated tablet - 400 milligram(s) - other drugs for treatment of tuberculosis; ethambutol

United States - English - NLM (National Library of Medicine)

sti pharma, llc - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - myambutol is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: myambutol plus isoniazid myambutol plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, myambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with myambutol have

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: magnesium stearate; polyethylene glycol monomethyl ether; maize starch; povidone; hypromellose; titanium dioxide; ethylcellulose; purified talc; propylene glycol; colloidal anhydrous silica - ethambutol lapl is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid pl

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; maize starch; purified talc; magnesium stearate; ethylcellulose; hypromellose; povidone; propylene glycol; polyethylene glycol monomethyl ether; titanium dioxide - ethambutol lapl is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculous meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculosis of the skin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjunction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies.,in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs ? ethambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months. for example:,? ethambutol plus isoniazid pl

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ethambutol hydrochloride, quantity: 400 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; gelatin; calcium hydrogen phosphate dihydrate; maize starch; ethylcellulose; sorbitol; titanium dioxide; macrogol 6000 - indications as at 04 jan 2002 : oral administation : myambutol is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculois meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculous of the shin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjuction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - myambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 months for example, myambutol plus isoniazid plus rifampicin or myambutol plus isoniazid plus streptomycin then continuing with a two drug regimen such as myambutol plus isoniazid or myambutol plus rifampicin. in patients who have received previous antituberculosis therapy, mycobacterial resistance to other durgs used in initial therapy is frequent. consequently, in such retreatment cases myambutol should be combined with at least one of the second-line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculosis drugs used with myambutol have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been use in multiple drug regimens. alternating drug regimens have also been utilised.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - ethambutol hydrochloride - oral tablet - 400mg